The Food & Drug Administration (FDA) has just recently approved the drug Dupixent for treating atopic dermatitis (eczema). It is a human monoclonal antibody (dupilumab) that targets two inflammatory molecules \u2013 IL-4 and IL-13 \u2013 the main driving forces for the rash and itch that characterize eczema. This drug is intended for people with moderate-to-severe eczema that is not otherwise controlled by antihistamines or topical steroids.<\/p>\n
The medicine is administered by subcutaneous injection from a pre-filled syringe. The current recommendation is that initial therapy be done in a doctor\u2019s office, but once safety is established, it can be done at home.<\/p>\n
The main side effects reported by the FDA are local injection site reactions, conjunctivitis and eye dryness and activation of oral herpes. Very rarely allergic reactions occurred.<\/p>\n
So far, it is only approved for non-pregnant adults. The drug trials demonstrated fairly dramatic results with 40% of participants having complete clearing of their rash within 16 weeks.<\/p>\n
Nemolizumab is an investigational monoclonal antibody that is showing real promise in treating moderate-to-severe atopic dermatitis (eczema). It inactivates Interleukin 31 (an inflammatory molecule associated with the often-intense itch of eczema).<\/p>\n","protected":false},"excerpt":{"rendered":"
The Food & Drug Administration (FDA) has just recently approved the drug Dupixent for treating atopic dermatitis (eczema). It is a human monoclonal antibody (dupilumab) that targets two inflammatory molecules \u2013 IL-4 and IL-13 \u2013 the main driving forces for the rash and itch that characterize eczema. This drug is intended for people with moderate-to-severe eczema that is not otherwise controlled by antihistamines or topical steroids. The medicine is administered by subcutaneous injection from a pre-filled syringe. The current recommendation…<\/p>\n